HDT Bio Announces Completion of Seed Financing Round

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

October 5, 2020

HDT Bio Corp., a biotechnology company enabling global access to immunotherapies for oncology and infectious disease, has announced the close of its seed financing round totaling ~$3 million. The round was co-led by Zoic Capital and joined by angel investors from multiple biotechnology hubs. Proceeds will be used largely to support the continued development of the company’s COVID-19 vaccine candidate, HDT-301.

HDT Bio notes the vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.

In addition to HDT-301, the company has a variety of other immunotherapy technologies highlighting different approaches to immune stimulation or modulation. Dr. Steven Reed, CEO of HDT, said of the funding and programs, “This investment, combined with our other sources of non-dilutive funding and early-stage revenue, puts us in a position to advance at least three products into the clinic in the next twelve months.”

Neal Mody, Managing Director at Zoic Capital, commented, “We’re excited to invest in HDT Bio and help the company grow to its full potential. HDT has multiple assets derived from exciting technology platforms that we see as a tremendously de-risking feature for companies at their stage.”

As the company expands operations it will complement an established research and discovery team with clinical development expertise. Existing HDT Bio leadership has decades of experience navigating the preclinical to clinical transition and will look to complement that with clinical staff versed in oncology and infectious disease trials.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.